Optimal detection of blood-brain barrier defects with Gd-DTPA MRI - The influences of delayed imaging and optimised repetition time

Magnetic Resonance Imaging

Volumn 14, Issue 4, 1996, Pages 373-380

  Tofts, Paul S ^a  

^a NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

Author keywords

Delayed scanning; Gd DTPA; Permeability; Triple dose

Indexed keywords

GADOLINIUM PENTETATE;

ARTICLE; BLOOD BRAIN BARRIER; BOLUS INJECTION; COMPUTER SIMULATION; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL;

EID: 0029930790     PISSN: 0730725X     EISSN: None     Source Type: Journal    
DOI: 10.1016/0730-725X(96)00023-9     Document Type: Article

References (28)

1. Niendorf, H.P.; Laniado, M.; Semmler, W.; Schorner, W.; Felix, R. Dose administration of gadolinium-DTPA in MR imaging of intracranial tumors. AJNR 8:803-815; 1987.
2. Schubeus, P.; Schorner, W.; Haustein, J. Dosing of Gd-DTPA in MR imaging of intracranial tumors. Magn. Reson. Med. 22:249-254; 1991.
3. Yuh, W.T.C.; Fisher, D.J.; Engelken, J.D.; Greene, G.M.; Sato, Y.; Ryals, T.J.; Crain, M.R.; Ehrhardt, J.C. MR evaluation of CNS tumors: Dose comparison study with gadopentetate dimeglumine and gadoteridol. Radiology 180:485-491; 1991.
4. Yuh, W.T.C.; Engelken, J.D.; Muhonen, M.G.; Mayr, N.A.; Fisher, D.J.; Ehrhardt, J.C. Experience with high-dose Gadolinium MR imaging in the evaluation of brain metastases. AJNR 13:335-345; 1992.
5. Runge, V.M.; Kirsch, J.E.; Burke, V.J.; Price, A.C.; Nelson, K.L.; Thomas, G.S.; Dean, B.L.; Lee, C. High-dose gadoteridol in MR imaging of intracranial neoplasms. J. Magn. Reson. Imaging 2:9-18; 1992.
6. Haustein, J.; Laniado, M.; Niendorf, H.-P.; Louton, T.; Beck, W.; Planitzer, J.; Schoffel, M.; Reiser, M.; Kaiser, W.; Schorner, W.; Hierholzer, J.; Traupe, H.; Hamm, B. Triple-dose vs. standard dose gadopentetate dimeglumine: A randomised study in 199 patients. Radiology 186:855-860; 1993.
7. Lee, D.; Kucharczyk, W.; Farb, R.; McClarty, B.; Trudel, G.C. Evaluation of additive doses of magnevist (gadopentetate dimeglumine) as an MRI contrast agent in detection of cerebral lesions. San Francisco: Society of Magnetic Resonance 2nd annual meeting; 1994: p. 445.
8. Vogl, T.J.; Friebe, C.E.; Mack, M.G.; Balzer, T.; Felix, R. MR evaluation of brain metastases: Comparison of standard and high-dose gadobutrol vs. standard dose Gd-DTPA. San Francisco: Society of Magnetic Resonance 2nd annual meeting; 1994: p. 548.
9. Filippi, M.; Campi, A.; Martinelli, V.; Colombo, B.; Yousry, T.; Canal, N.; Scotti, G.; Comi, G. Comparison of triple dose vs. standard dose Gadolinium-DTPA for detection of MRI enhancing lesions in patients with primary progressive multiple sclerosis. J. Neurol. Neurosurg. Psychol. 59:540-544; 1995.
10. Schorner, W.; Laniado, M.; Niendorf, H.P.; Schubert, C.; Felix, R. Time-dependent changes in image contrast in brain tumors after gadolinium-DTPA. AJNR 7:1013-1020; 1986.
11. Davis, P.C.; Gokhale, K.A.; Joseph, G.J.; Peterman, S.B.; Adams, D.A.; Tindall, G.T.; Hudgins, P.A.; Hoffman, J.C. Pituitary adenoma: Correlation of half-dose gadolinium-enhanced MR imaging with surgical findings in 26 patients. Radiology 180:779-784; 1991.
12. Tofts, P.S.; Kermode, A.G. Measurement of the Blood-Brain Barrier permeability and leakage space using dynamic MR imaging - 1. Fundamental concepts. Magn. Reson. Med. 17:357-367; 1991
13. Tofts, P.S. Optimal detection of blood-brain barrier defects with Gd-DTPA - The influence of delayed imaging and optimised repetition time. Nice, France: Society of Magnetic Resonance 3rd annual meeting; 1995: p. 1296.
14. Berkowitz, B.A.; Tofts, P.S.; Sen, H.A.; Ando, N.; de Juan, E. Accurate and precise measurement of blood-retinal barrier breakdown using dynamic Gd-DTPA MRI. Invest. Ophthalmol. Vis. Sci. 33:3500-3506;1992.
15. Tofts, P.S.; Berkowitz, B.; Schnall, M.D. Quantitative analysis of dynamic Gd-DTPA enhancement in breast tumors using a permeability model. Magn. Reson. Med. 33:564-568; 1995.
16. Weinmann, H.J.; Laniado, M.; Mutzel, W. Pharmacokinetics of GdDTPA/Dimeglumine after intravenous injection into healthy volunteers. Physiol. Chem. Phys. Med. NMR 16:167-172; 1984.
17. Tofts, P.S.; Shuter, B.; Pope, J.M. Ni-DTPA doped agarose gel - A phantom material for Gd-DTPA enhancement measurements. Magn. Reson. Imaging 11:125-133; 1993.
18. Tofts, P.S.; Berkowitz, B.A. Rapid measurement of capillary permeability using the early part of the dynamic Gd-DTPA MRI enhancement curve. J. Magn. Reson. part B 102:129-136; 1993.
19. Wehrli, F.W. Fast-Scan Magnetic Resonance. 1st ed. New York: Raven Press; 1991: p. 12.
20. 2 in the brain of patients with severe but stable multiple sclerosis. Magn. Reson. Med. 7:43-55; 1988.
21. Kermode, A.G.; Tofts, P.S.; Thompson, A.J.; MacManus, D.G.; Rudge, P.; Kendall, B.E.; Kingsley, D.P.E.; Moseley, I.F.; du Boulay, E.P.G.H.; McDonald, W.I. Heterogeneity of blood-brain barrier changes in multiple sclerosis: An MRI study with gadolinium-DTPA enhancement. Neurology 40:229-235; 1990.
22. Wang, L.; Lai, H.M.; Lemieux, L.; Tofts, P.S. Detection of disease activity in multiple sclerosis by subtraction of serial image data sets. Nice, France: Society of Magnetic Resonance 3nd meeting; 1995: p. 710.
23. Tofts, P.S.; Kermode, A.G.; MacManus, D.G.; Robinson, W.H. Nasal orientation device to control head movement during CT and MR studies. J. Comput. Assist. Tomogr. 14:163-164; 1990.
24. MacManus, D.G.; Kermode, A.G.; Tofts, P.S. A repositioning technique for cerebral magnetic resonance imaging of patients with multiple sclerosis. Amsterdam: Society of Magnetic Resonance in Medicine 8th annual meeting; 1989: p. 617.
25. Hajnal, J.V.; Saeed, N.; Oatridge, A.; Williams, E.J.; Young, I.R.; Bydder, G.M. Detection of subtle brain changes using subvoxel registration and subtraction of serial MR images. J. Comput. Assist. Tomogr. 19:677-691; 1995.
26. Wood, G.K.; Berkowitz, B.A.; Wilson, C.A. Visualization of subtle contrast-related intensity changes using temporal correlation. Magn. Reson. Imaging 12:1013-1020; 1994.
27. Su, M.; Jao, J.; Nalcioglu, O. Measurement of vascular volume fraction and blood-tissue permeability constants with a pharmacokinetic model: Studies in rat muscle tumors with dynamic Gd-DTPA enhanced MRI. Magn. Reson. Med. 32:714-724; 1994.
28. Filippi, M.; Yousry, T.; Campi, A.; Kandziora, C.; Colombo, B.; Voltz, R.; Martinelli, V.; Spuler, S.; Bressi, S.; Scotti, G.; Comi, G. Comparison of triple dose versus standard dose gadolinium-DTPA for detection of MRI enhancing lesions in patients with multiple sclerosis. Neurology 46:379-384; 1996.